UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 10, 2005
(Exact name of registrant as specified in its charter)
|
MASSACHUSETTS |
|
000-19319 |
|
04-3039129 |
|
(State or other jurisdiction of |
|
(Commission File Number) |
|
(IRS Employer Identification |
|
|
|
|
|
|
|
130 Waverly Street |
||||
|
Cambridge, Massachusetts 02139 |
||||
|
(Address of principal executive offices) (Zip Code) |
||||
|
|
|
|
|
|
|
(617) 444-6100 |
||||
|
Registrant’s telephone number, including area code: |
||||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01. Other Events.
On June 10, 2005, Vertex Pharmaceuticals Incorporated issued a press release that announced the initiation of dosing in a Phase II clinical study with VX-702, an investigational oral p38 MAP kinase inhibitor, for the treatment of rheumatoid arthritis. A copy of that press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(c) Exhibits
|
Exhibit |
|
Description of Document |
|
|
|
|
|
99.1 |
|
Press Release of Vertex Pharmaceuticals Incorporated, dated June 10, 2005, titled “Vertex Pharmaceuticals Initiates Phase II Clinical Study in Rheumatoid Arthritis with Investigational Oral p38 MAP Kinase Inhibitor VX-702”. |
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
VERTEX PHARMACEUTICALS |
||
|
|
(Registrant) |
||
|
|
|
||
|
Date: June 10, 2005 |
/s/ Kenneth S. Boger |
|
|
|
|
Kenneth S. Boger |
||
|
|
Senior Vice President and General Counsel |
||
2